US · AKBA · BIOTECHNOLOGY
Akebia Therapeutics, Inc. (AKBA) intrinsic value and stock valuation
$0.39as of 2026-11-21 · Mkt cap 346.05M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Akebia Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values AKBA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AKBA’s statements →
Akebia Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Corvus Pharmaceuticals, Inc. (CRVS) $9.67
- Olema Pharmaceuticals, Inc. (OLMA) $7.02
- Rigel Pharmaceuticals, Inc. (RIGL) $40.09
- Zevra Therapeutics, Inc. (ZVRA) $8.76
- 4D Molecular Therapeutics, Inc. (FDMT) $10.23
- Prothena Corporation plc (PRTA) $8.22
- Compass Therapeutics, Inc. (CMPX) $0.69
- Gossamer Bio, Inc. (GOSS) $10.72
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M | $211.7M |
| Operating income | $23.5M | -$-50.47M | -$-46.26M | -$-80.78M | -$-264.5M |
| Net income | -$-5.34M | -$-69.41M | -$-51.92M | -$-94.23M | -$-282.02M |
| EPSd | -$-20.77K | -$-329.04K | -$-276.95K | -$-515.54K | -$-1.7M |
| Operating cash flow | $68M | -$-40.66M | -$-23.38M | -$-73.15M | -$-252.97M |
| Capital expenditure | -$-290K | -$-30K | $0.00 | -$-110K | -$-60K |
| Free cash flow | $68M | -$-40.69M | -$-23.38M | -$-73.27M | -$-253.02M |
| Total assets | $376.6M | $220.7M | $241.7M | $356.1M | $529.4M |
| Total debt | $216.3M | $188.7M | $104.2M | $99.8M | $189.1M |
| Net debt | $31.5M | $136.9M | $61.3M | $9.32M | $39.3M |
| Total equity | $32.6M | -$-49.19M | -$-30.58M | $5.23M | $74M |
| Cash and short-term investments | $184.8M | $51.9M | $42.9M | $90.5M | $149.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M | $211.7M |
| Cost of revenue | $39.5M | $63.2M | $74.2M | $22.5M | $81.5M |
| Gross profit | $196.7M | $97M | $120.5M | $270M | $130.2M |
| Research and development expenses | $62.4M | $37.7M | $63.1M | $166M | $147.9M |
| Selling, general and administrative expenses | $107.5M | $106.6M | $100.2M | $138.6M | $174.1M |
| Other expenses | $3.4M | $3.28M | $3.42M | $46.2M | $72.7M |
| Operating expenses | $173.2M | $147.5M | $166.7M | $350.8M | $394.7M |
| Cost and expenses | $212.7M | $210.7M | $240.9M | $373.3M | $476.2M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $24.2M | $18.2M | $6.03M | $15.7M | $19.9M |
| Depreciation and amortization | $1.27M | $37.5M | $37.6M | $37.7M | $38M |
| Ebitda | $21.7M | -$-13.72M | -$-8.27M | $3.06M | -$-189.91M |
| Operating income | $23.5M | -$-50.47M | -$-46.26M | -$-80.78M | -$-264.5M |
| Total other income/expenses, net | -$-27.22M | -$-18.94M | -$-5.67M | -$-13.45M | -$-17.52M |
| Income before tax | -$-3.72M | -$-69.41M | -$-51.92M | -$-94.23M | -$-282.02M |
| Income tax expense | $1.62M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-5.34M | -$-69.41M | -$-51.92M | -$-94.23M | -$-282.02M |
| Weighted average shares outstanding | $257.2M | $211M | $187.5M | $182.8M | $166M |
| Weighted average diluted shares outstanding | $257.2M | $211M | $187.5M | $182.8M | $166M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $184.8M | $51.9M | $42.9M | $90.5M | $149.8M |
| Net receivables | $47M | $34.4M | $39.3M | $40.3M | $51.6M |
| Inventory | $15.6M | $16.2M | $15.7M | $21.6M | $36.6M |
| Total current assets | $184.8M | $113.8M | $118.2M | $185.2M | $271.2M |
| Property, plant and equipment, net | $0.00 | $10.4M | $16.1M | $34.4M | $40.6M |
| Goodwill and intangible assets | $59M | $59M | $95.1M | $131.1M | $167.2M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $191.7M | $106.8M | $123.6M | $170.9M | $258.2M |
| Total assets | $376.6M | $220.7M | $241.7M | $356.1M | $529.4M |
| Accounts payable | $21.2M | $15.2M | $14.6M | $18M | $33.6M |
| Short-term debt | $40.1M | $9.71M | $24M | $36.7M | $102.3M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $3.74M | $20.9M |
| Total current liabilities | $162.9M | $80.9M | $99.9M | $129.5M | $261.1M |
| Long-term debt | $176.2M | $179M | $80.1M | $63M | $86.8M |
| Deferred revenue, non-current | $0.00 | $0.00 | $43.3M | $43.3M | $21.5M |
| Total non-current liabilities | $181M | $188.9M | $172.4M | $221.3M | $194.3M |
| Capital lease obligations | $0.00 | $8.95M | $13.4M | $33.7M | $38.5M |
| Total liabilities | $344M | $269.9M | $272.3M | $350.8M | $455.3M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-1.68B | -$-1.68B | -$-1.61B | -$-1.56B | -$-1.46B |
| Accumulated other comprehensive income (loss) | $10K | $10K | $10K | $10K | $10K |
| Total equity | $32.6M | -$-49.19M | -$-30.58M | $5.23M | $74M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $216.3M | $188.7M | $104.2M | $99.8M | $189.1M |
| Net debt | $31.5M | $136.9M | $61.3M | $9.32M | $39.3M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-5.34M | -$-69.41M | -$-51.92M | -$-92.56M | -$-282.02M |
| Depreciation and amortization | $1.27M | $37.5M | $41.9M | $37.7M | $36.1M |
| Stock-based compensation | $11.3M | $7.78M | $9.32M | $17.9M | $22.7M |
| Change in working capital | $16.5M | -$-39.68M | -$-20.73M | -$-1.44M | -$-105.61M |
| Accounts receivable | -$-14.14M | $4.05M | $990K | $11.7M | -$-24.03M |
| Inventory | -$-23.12M | -$-28.4M | -$-2.54M | $19.8M | -$-24.95M |
| Accounts payable | $3.08M | -$-1.36M | -$-5.24M | $1.5M | -$-11.73M |
| Net cash provided by operating activities | $68M | -$-40.66M | -$-23.38M | -$-73.15M | -$-252.97M |
| Investments in property, plant and equipment | $0.00 | -$-30K | $0.00 | -$-110K | -$-60K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-7.93M | -$-30K | $0.00 | -$-110K | $39.9M |
| Common stock issued | $68.4M | $42.7M | $6.79M | $7.53M | $89M |
| Common stock repurchased | $0.00 | -$-1.27M | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $72.9M | $49.7M | -$-25.21M | $14.6M | $133.7M |
| Net change in cash | $133M | $8.97M | -$-48.59M | -$-58.67M | -$-79.29M |
| Cash at end of period | $186.5M | $53.6M | $44.6M | $93.2M | $149.8M |
| Operating cash flow | $68M | -$-40.66M | -$-23.38M | -$-73.15M | -$-252.97M |
| Capital expenditure | -$-290K | -$-30K | $0.00 | -$-110K | -$-60K |
| Free cash flow | $68M | -$-40.69M | -$-23.38M | -$-73.27M | -$-253.02M |
Line items
Line items
Line items
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
- CEO
- John Butler
- Employees
- 194
- Beta
- 0.23
Explore
Frequently asked questions
What is the intrinsic value of Akebia Therapeutics, Inc. (AKBA)?
InvestorsCraft does not currently publish an intrinsic value for AKBA. How the IC value is calculated.
Is AKBA undervalued?
InvestorsCraft does not publish an undervaluation signal for AKBA at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.